CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.

Century Bancorp is a bank holding company. Through its subsidiary, Century Bank and Trust Company, the company provides services to commercial enterprises, state and local governments and agencies, non-profit organizations and individuals. The company also provides securities brokerage services through a program called Investment Services at Century Bank, which is supported by LPL Financial, a third party securities brokerage business. The company grants single-family and multi-family residential loans, commercial and commercial real estate loans, municipal loans, and a variety of consumer loans. In addition, the company provides savings accounts, NOW accounts, demand deposits, time deposits and money market accounts.

Frequency Electronics is engaged in precision time and frequency generation technology. The company's segments are: FEI-NY and FEI-Zyfer. The FEI-NY segment includes the operations of the company's wholly-owned subsidiaries, FEI-Asia and FEI-Elcom. FEI-Asia functions as a manufacturing facility for FEI-NY and FEI-Zyfer. FEI-Elcom provides design and technical support for the FEI-NY segment's business. The FEI-Zyfer segment designs and manufactures products which incorporate global positioning systems technologies and clocks designed and manufactured at FEI-NY. FEI-Zyfer sells its products to both commercial and U.S. Government customers and collaborates with FEI-NY on joint product development activities.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. The company is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and other hematologic cancers. The company is also developing an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4.

Marchex is a call analytics company that helps businesses connect, drive, measure and convert callers into customers. The company's primary product offerings include: Marchex Call Analytics, which is an analytics platform for enterprises; Marchex Display and Video Analytics, which is a product for marketers that buy digital display advertising; Marchex Site Analytics, which is a product for marketers that can drive phone calls from websites; Marchex Social Analytics, which is a product for marketers that buy social media advertising; Marchex Call Marketplace, which is a mobile advertising network for businesses; and Local Leads, which is an advertising solution for small business resellers.